Presentation highlights potential for VG-3927 to treat neurodegenerative diseases associated with microglial dysfunction, like AD, due to its differentiated neuroprotective profile and ability to ...
- First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer’s disease (AD) - “We are thrilled to showcase our preclinical and Phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results